Format

Send to

Choose Destination
Curr Opin Biotechnol. 2017 Dec;48:119-126. doi: 10.1016/j.copbio.2017.03.025. Epub 2017 Apr 26.

Switchable Cas9.

Author information

1
Bayer AG, Pharmaceuticals, Protein Engineering and Assays, 50829 Köln, Germany. Electronic address: florian.richter@bayer.com.
2
Max Planck Institute for Infection Biology, 10117 Berlin, Germany; The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå Centre for Microbial Research (UCMR), Department of Molecular Biology, Umeå University, Umeå 90187, Sweden. Electronic address: fonfara@mpiib-berlin.mpg.de.
3
Universität Bayreuth, Lehrstuhl für Biochemie, Bayreuth, Germany.
4
Max Planck Institute for Infection Biology, 10117 Berlin, Germany; The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå Centre for Microbial Research (UCMR), Department of Molecular Biology, Umeå University, Umeå 90187, Sweden.
5
Universität Bayreuth, Lehrstuhl für Biochemie, Bayreuth, Germany; Universität Bayreuth, Research Center for Bio-Macromolecules, Bayreuth, Germany.

Abstract

Ever since its discovery, Cas9 from Streptococcus pyogenes has revolutionized biology by enabling analysis and engineering of genomes with unprecedented precision and ease. To fine-tune on-target effects and to mitigate adverse effects caused by untimely and off-target action of Cas9, strategies have been developed to control its activity at the post-translational stage via external trigger signals. Control is either achieved by modifying the Cas9 protein itself or its programmable RNA molecules. To date, switchable Cas9 variants responding to small ligands, light or temperature have been engineered. With these variants in hand, the regulation and modification of genomes can be accomplished in graded and ever more precise manner.

PMID:
28456061
DOI:
10.1016/j.copbio.2017.03.025
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center